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Abstract
Background:  The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based
chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of
metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3rd or later-line, alone or
with 5FU. The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX
in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin.
Methods: Thirty one consecutive patients treated between May 2005 and October 2006 were included in this
retrospective study. All of them have progressed under a chemotherapy with fluoropyrimidine plus irinotecan
and/or oxaliplatin and received bevacizumab (5 mg/kg) in combination with FOLFIRI or simplified FOLFOX4 every
14 days.
Results: Ten patients (32.2%) had an objective response (1 CR, 9 PR) and 12 (38.8%) were stabilized. The
response and disease control rates were 45.4% and 100% when bevacizumab was administered in 2nd or 3rd line
and 25% and 55% in 4th or later line respectively (p = 0.024 and p = 0.008). Among the patients who had previously
received the same chemotherapy than that associated with bevacizumab (n = 28) the overall response rate was
35.7% and 39.3% were stabilized. Median progression free survival (PFS) and overall survival (OS) were of 9.7 and
18.4 months respectively. Except a patient who presented a hypertension associated reversible posterior
leukoencephalopathy syndrome, tolerance of bevacizumab was acceptable. A rectal bleeding occurred in one
patient, an epistaxis in five. Grade 1/2 hypertension occurred in five patients.
Conclusion: This study suggests that bevacizumab combined with FOLFOX or FOLFIRI may have the possibility
to be active in chemorefractory and selected mCRC patients who did not receive it previously.
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Background
Colorectal cancer (CRC) is one of the most common
human malignancies with more than 300,000 cases both
in the United States and in the European Union each year.
In the past decade, significant improvements have been
performed in response rates, progression-free survival
(PFS) and overall survival (OS) [1-4]. Despite these
improvements, mainly due to the development of new
combinations of standard chemotherapy including 5
fluorouracil, irinotecan and oxaliplatin, nearly all patients
with metastatic CRC (mCRC) will die from their disease.
Recently, new therapeutic agents targeting molecular
events involved in colorectal carcinogenesis have been
developed, including bevacizumab, a recombinant
humanized monoclonal antibody, which binds to the vas-
cular endothelial growth factor (VEGF) with a high specif-
icity and prevents its interaction with receptors on
endothelial cells. VEGF plays a key role in angiogenesis,
which is involved in the development of carcinogenesis,
tumor growth and malignant dissemination. Therefore,
bevacizumab inhibits the activation of VEGF-receptor-
mediated signaling pathways and resultant biological
effects [5]. This antiangiogenic agent, added to a 5-fluor-
ouracil (5FU) ± irinotecan-based chemotherapy as first-
line treatment, has been shown to improve response rates
and survival of mCRC patients when compared to the
chemotherapy alone [6-8]. An improvement of PFS was
also shown in first-line with the addition of bevacizumab
to oxaliplatin-based chemotherapy [9]. A randomized
phase III study also reported a clinical efficacy of the asso-
ciation of bevacizumab and FOLFOX4 as second-line in
mCRC patients previously treated with a fluoropyrimi-
dine and irinotecan, with a significant improvement in
response rates, PFS and OS when compared to FOLFOX4
alone [10].
In Europe, bevacizumab was approved by the EMEA
(European Medicines Evaluation Agency) in the begin-
ning of 2005 and many CRC patients could not have
received it in first or second-line treatment before this
date. Moreover, it was reported to have no efficacy in 3rd
or later-line, alone or with 5FU [10,11]. The aim of this
retrospective study was to evaluate the activity of bevaci-
zumab combined with a chemotherapy with 5FU/LV and
irinotecan or oxaliplatin in mCRC who have failed prior
chemotherapy with fluoropyrimidine plus irinotecan
and/or oxaliplatin.
Methods
Patient characteristics
In this retrospective study, we included all the patients
prospectively registered in two centers (Hôpital Ambroise
Paré, Boulogne Billancourt and Centre Régional de Lutte
contre le Cancer Val d'Aurelle, Montpellier, France) with
histologically proven mCRC who had been previously
treated with a fluoropyrimidine (e.g., fluorouracil or
capecticabine) plus irinotecan and/or oxaliplatin with no
response to treatment (as defined by tumor progression
according to the RECIST criteria [12] or unacceptable tox-
icity) and who then received bevacizumab in combina-
tion with FOLFIRI or simplified FOLFOX4 between May
2005 and October 2006. The decision of treatment was
always taken during multidisciplinary staff for patients
who had not the opportunity to receive bevacizumab at
an earlier line of chemotherapy. The usual exclusion crite-
ria were a history of major surgery within 28 days, a
thrombotic or bleeding event within 6 months, a hyper-
tension, a clinically significant cardiovascular disease, a
hypertension, a therapeutic anticoagulation and the pres-
ence of brain metastases. All medical files of the patients
were registered prospectively in a computerised database
(after national registry council (CNIL) authorization). The
following data were collected and analyzed: age and per-
formance status (according to WHO criteria) at the time of
the first cycle of bevacizumab, gender, primary tumor site
(colon or rectum), number and localization of metastatic
sites, previous anticancer drugs received and tumor
response to them. This retrospective study was proposed
in January 2007 and approved by the local scientific and
ethical committee.
Treatment protocols
Patients were treated with bevacizumab given at a dose of
5 mg/kg on day 1 every two weeks, followed by a 2-hour
infusion of 400 mg/m2 of leucovorin, given simultane-
ously with a 2-hour infusion of 85 mg/m2 of oxaliplatin,
followed by a bolus of 400 mg/m2 of 5FU and then a 46-
hour infusion of 2400 mg/m2  of 5FU (simplified
FOLFOX4) or the same regimen with a 90 minutes (min)
infusion of 180 mg/m2 of irinotecan instead of the infu-
sion of oxaliplatin (FOLFIRI) (1 cycle = 14 days). The first
infusion of bevacizumab was given over 90 min, the sec-
ond over 60 min and the following over 30 min when pre-
vious infusions were well tolerated.
Tumor evaluation
All the patients must have received at least four cycles of
chemotherapy with bevacizumab to be evaluable, but two
patients had evidence of a clinical progression before the
radiologic evaluation of tumor response and received
only three cycles of bevacizumab.
Tumour response was prospectively assessed every four
cycles according to RECIST criteria by computerized tom-
ography-scan. Treatment was repeated until the occur-
rence of disease progression or unacceptable toxicity.
Toxicity was assessed according to the Common Toxicity
Criteria version 2.0[13].BMC Cancer 2009, 9:347 http://www.biomedcentral.com/1471-2407/9/347
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Statistical analysis
Fisher's exact test was used to compare response and sta-
bilization rates between groups. The PFS was calculated as
the period from the first day of bevacizumab treatment to
the date of tumor progression, to death from any cause or
to the date of the last follow-up at which data point was
censored. The OS time was calculated as the period from
the first day of bevacizumab treatment until death of any
cause or until the date of the last follow-up, at which data
point was censored. Both PFS and OS were estimated by
the Kaplan-Meier method and compared using the log-
rank test. Analysis was carried out using the STATA soft-
ware package (College Station, Texas). The level of signif-
icance was set at p = 0.05.
Results
Patient characteristics
Between May 2005 and October 2006, a total of 31
patients (17 men, 14 women, median age: 60 years) with
mCRC resistant to fluoropyrimidine plus irinotecan
(96.7%) and/or oxaliplatin (90.3%) received bevacizu-
mab combined with FOLFIRI or FOLFOX4. A total of 373
cycles of bevacizumab combined with chemotherapy
were administered, with a median of 12 cycles per patient
(range: 3 to 35 cycles).
Patients characteristics are detailed in the table 1. All the
patients had a good WHO performance status (≤ 2) at the
beginning of bevacizumab therapy except one (WHO PS
= 3). The number of metastatic sites were limited to one
or two organs in 77% of the cases (24 patients), and
metastases were mostly located in the liver (84%) or lung
(42%). Twenty seven patients (87%) had previously
received fluoropyrimidine, irinotecan and oxaliplatin and
19 (61%) had received cetuximab. In 19 out of 20 patients
who received bevacizumab in 4th-line or further (L4+),
cetuximab was previously used and failed, five patients
previously received a monotherapy of fluoropyrimidine
(capecitabine ou 5FU), four patients were treated by the
association of capecitabine and mitomycin-C and five by
hepatic arterial infusion of oxaliplatin and intraveinous
LV5FU2. Bevacizumab was combined with FOLFIRI in 19
cases and with FOLFOX in 12 cases and was administered
equally as third, fourth and fifth or later-line (32% in each
group). One patient was treated in second line but he was
progressive under a combination of 5FU, irinotecan and
oxaliplatine (FOLFIRINOX regimen).
Response rates
The overall response rate was 32.2% (table 2). One
patient (3.2%) had a complete response and 9 (29%) a
partial response. Among them, one patient could have a
resection of liver metastases after a partial response to
FOLFIRI plus bevacizumab and was alive without relapse
at the last follow-up. Twelve patients (38.8%) had a stable
disease, with a disease control rate of 71%. The response
rate was 45.4% when bevacizumab was administered in
2nd and 3rd-line (L2-L3) and 25% when it was adminis-
tered in 4th-line and further (L4+) respectively (table 2; p
= 0.024). It was 36.9% when bevacizumab was associated
with FOLFIRI and 25% when associated with FOLFOX (p
= 0.6). The disease control rate was 100% when bevacizu-
mab was administered in L2-L3 and 55% when it was
administered in L4+ respectively (table 2; p = 0.008). Most
of the patients (n = 28; 90%) had previously received the
same chemotherapy (FOLFOX or FOLFIRI) than that asso-
ciated with bevacizumab. Among these patients, the over-
all response rate was 35.7% and 39.3% were stabilized
(table 2).
Survival
With a median follow-up period of 35.9 months (range:
33 to 37.4 months) from the beginning of bevacizumab
administration, the median PFS was 9.7 months (95%
confidence interval (CI): 6.6-13.6) (figure 1) and the
Table 1: Patients characteristics
Characteristics
Sex: Male/Female 17/14
Age (years)
Median 60
Range 24-81
WHO Performance status, n(%)
0 10 (32)
1 16 (52)
24  ( 1 3 )
31  ( 3 )
Primary tumor location, n (%)
Colon 23
Rectum 8
Metastatic sites, n (%)
Liver 26 (84)
Lung 13 (42)
Peritoneum 5 (16)
Others 12 (39)
Number of metastatic sites, n (%)
1 15 (48)
2 10 (32)
≥ 37  ( 2 3 )
Chemotherapy associated with bevacizumab, n (%)
FOLFIRI 19 (61)
FOLFOX4 12 (39)
Line number of bevacizumab, n (%)
2nd line 1(3.25)
3rd line 10 (32.25)
4th line 10 (32.25)
5th or later-line 10 (32.25)
Previous chemotherapy
Fluoropyrimidine + irinotecan + oxaliplatin 27
Fluoropyrimidine + irinotecan 3
Fluoropyrimidine + oxaliplatin 1
Cetuximab 19BMC Cancer 2009, 9:347 http://www.biomedcentral.com/1471-2407/9/347
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median OS was 18.4 months (95%CI: 13.6- not reached)
(figure 2).
Toxicity
There was no toxic death. The incidence of haematologi-
cal and non-hematological toxicity is summarized in
Table 3. A grade 3/4 toxic event occurred in 19,3% of
patients. A cytotoxic dose reduction or interruption and a
delay in chemotherapy cycles was required in 51% and
13% of patients respectively. As concerns bevacizumab-
induced toxicity, only one interruption was required in a
patient who presented a reversible posterior leukoen-
cephalopathy syndrome attributed to bevacizumab ther-
apy because of associated hypertension. This syndrome
was revealed by a generalized tonic-clonic seizure and
diagnosed on magnetic resonance imaging of the brain
[14]. Except this severe adverse event, tolerance of bevaci-
zumab was acceptable, without bowel perforation,
thromboembolism event, severe bleeding or hyperten-
sion. A minimal rectal bleeding occurred in one patient
and a grade 1/2 hypertension in five patients, which was
easily manageable by an antihypertensive treatment. An
epistaxis also occurred in five patients.
Discussion
This study reports an activity of bevacizumab at the dose
of 5 mg/kg combined with FOLFOX or FOLFIRI regimen
in patients who have failed prior chemotherapy with
fluoropyrimidine, irinotecan and/or oxaliplatin. Indeed,
32% of the patients could achieved an objective response
and one patient could secondary have a curative resection
of its liver metastases. The disease control rate was supe-
rior to 70%. The addition of bevacizumab to FOLFIRI or
FOLFOX was also associated with a PFS and a OS of 9.7
months and 18.4 months respectively. These response
and survival rates are higher than those reported by Gian-
tonio et al. with the combination of FOLFOX plus bevaci-
zumab in second line treatment in patients previously
treated by fluoropyrimidine and irinotecan, but this
might be certainly explained by the small size and the ret-
Table 2: Overall response rates
Patients (n) CR (%) PR (%) SD (%) PD (%)
Overall 31 1 (3.2) 9 (29) 12 (38.8) 9 (29)
2nd and 3rd line 11 0 (0) 5 (45.5) 6 (55.5) 0 (0)
4th and later line 20 1 (5) 4 (20) 6 (30) 9 (45)
FOLFIRI 19 1 (5.3) 6 (31.6) 8 (42.1) 4 (2.1)
FOLFOX 12 0 (0) 3 (25) 4 (33.3) 5 (41.7)
Same CT previously used
Yes 29 1 (3.5) 9 (31) 11 (37.9) 8 (27.6)
No 2* 0 (0) 0 (0) 1 (50) 1 (50)
CR; complete response, CT; chemotherapy; PR; partial response, SD; stable disease, PD; progression disease. * no previous treatment by FOLFOX 
in two patients treated by bevacizumab + FOLFOX
This figure displays a graph showing 'Progression free sur- vival' Figure 1
This figure displays a graph showing 'Progression free 
survival'.
This figure displays a graph demonstrating 'Overall survival' Figure 2
This figure displays a graph demonstrating 'Overall 
survival'.BMC Cancer 2009, 9:347 http://www.biomedcentral.com/1471-2407/9/347
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rospective nature of our study. Furthermore, patients who
received bevacizumab during the period of the study were
highly selected because bevacizumab was not registered in
this setting but only in first line treatment. For these rea-
sons, our results have to be taken with caution. However,
they are nonetheless interesting in third-line treatment
where few molecules have been shown to be effective. In
patients pretreated with fluroropyrimidine, irinotecan
and/or oxaliplatin, several studies have reported poor
response and survival rates with standard chemotherapy
such as the association of mitomycine C and capecitabine
[15-18]. The antibodies against the Epidermal Growth
Factor Receptor (EGFR) are the only therapy to have
shown their efficacy in chemorefractory CRC patients.
Cetuximab was the first to show a significant response rate
in association with irinotecan in irinotecan-refractory
mCRC in the phase II BOND study, in which PFS and OS
were of 4.1 and 8.6 months respectively [19]. The superi-
ority of cetuximab monotherapy over best supportive care
(BSC) in terms of survival was demonstrate more recently
[20]. The fully human anti-EGFR antibody panitumumab
was also associated with a longer PFS when compared to
BSC in a recent randomized phase III trial [21]. However,
it is now clearly demonstrated that patients with a tumor
KRAS mutation are resistant to anti-EGFR antibodies and
do not benefit from this targeted therapy [22-26]. Bevaci-
zumab should therefore be considered for these patients
after failure of conventional chemotherapy. In our study,
61% of the patients had previously received cetuximab
and were so resistant to all potentially efficient therapies
approved in the treatment of mCRC.
In patients who were previously treated with the same
chemotherapy regimen (90% of all patients included), the
addition of bevacizumab to this regimen allowed a
response rate of 35.7% and a stabilization of 39.3%,
which suggests that the antiangiogenic therapy may cir-
cumvent resistance to conventional chemotherapy by
allowing a more efficient delivery of chemotherapeutic
agents. Tumor vasculature is structurally and functionally
abnormal, which results in an heterogeneity in tumor
blood flow with interstitial hypertension, hypoxia and
acidosis [27]. Hypoxia could therefore renders tumor cells
resistant to several cytotoxic drugs by interfering with the
penetration of these drugs throughout the tumor. The
concept of "normalization" of tumor vasculature induced
by bevacizumab, developed by Jain [28] who demon-
strated with some colleagues this effect of VEGF blockade
in rectal carcinoma [29], may therefore explain the cir-
cumvention of resistance to conventional therapies
observed in our study. This phenomenon do not seem to
be observed with the combination of an anti-EGFR anti-
body with bevacizumab considering the disappointing
results of two recent randomized studies in which the
addition of cetuximab or panitumumab to bevacizumab
in combination with a conventional chemotherapy was
not associated with any benefit but on the contrary per-
haps with a deleterious effect [30,31], which remains to
be elucidated.
A first randomized phase II trial of bevacizumab plus
bolus 5FU/LV compared to 5FU/LV alone in untreated
mCRC suggested an improvement of response rate, PFS
and OS with the combined treatment [7]. Then, the large
randomized phase III study reported by Hurwitz et al. [6]
demonstrated that the addition of bevacizumab to iri-
notecan and bolus 5FU/LV (IFL regimen) in first-line
treatment was associated with a significant prolongation
of PFS (6.2 months versus 10.6 months) and OS (15.6
months versus 20.3 months), as a better response rate
(34.8% versus 44.8%). The results of that pivotal study led
to the registration of bevacizumab in the fist-line setting
in the United States and in Europe. The association of bev-
acizumab to 5FU/LV was also shown to provide a statisti-
cally significant and clinically relevant benefit to patients
with previously untreated mCRC [6-8,32]. More recent
Table 3: Chemotherapy-induced toxicity (NCI-CTC version 2.0)
Grade 1, n Grade 2, n Grade 3, n Grade 4, n
N e u t r o p e n i a 0310
T h r o m b o c y t o p e n i a 2100
A n e m i a 0210
D i a r r h e a 1 0 410
Nausea-vomiting 10 9 2 0
A l o p e c i a 3000
H a n d - f o o t  s y n d r o m e 0100
m u c o s i t i s 6020
N e u r o t o x i c i t y 3340
A s t h e n i a 9730
A l l e r g i c  r e a c t i o n 0100
Maximum/patient (%) 4 (12,9) 15 (48,4) 6 (19,3) 0 (0)
NCI-CTC: National Cancer Institute Common Toxicity Criteria.BMC Cancer 2009, 9:347 http://www.biomedcentral.com/1471-2407/9/347
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studies showed that bevacizumab with FOLFIRI or
FOLFOX4 regimen was superior to the chemotherapy
alone in this setting [9,33]. In second-line, the ECOG
E3200 phase III trial showed that bevacizumab improved
response rate, PFS and OS when added to the FOLFOX4
regimen in patients pre-treated with a fluoropyrimidine
and irinotecan [10]. Bevacizumab in combination with
5FU/LV plus irinotecan or oxaliplatin is therefore proved
to be beneficial in first and 2nd-line setting. In the absence
of cross-over after progression in the chemotherapy arm
of the studies evaluating the addition of bevacizumab to a
combined chemotherapy [6,10], the effect of the antiang-
iogenic agent associated with a bichemotherapy after the
2nd-line of treatment is not known. However, it was asso-
ciated with a poor response rate (1%) in combination
with a bolus regimen of 5FU/LV in chemotherapy-refrac-
tory mCRC [11]. In this large multicenter phase II study,
PFS and OS were 3.7 months and 9.1 months respectively.
This result, adding to the lack of efficacy of bevacizumab
in monotherapy[10] led us to test it in this setting in com-
bination with the more active FOLFOX4 or FOLFIRI regi-
mens. Bevacizumab was administrated at the dose of 5
mg/kg every 2 weeks as it was reported in first-line studies
with 5FU/LV/irinotecan or oxaliplatin [6,9,33] and since
the 10 mg/kg dose was not previously shown to be supe-
rior [7].
Our results are consistent with those of a recent small
study conducted in 14 mCRC patients that progressed
after oxaliplatin and irinotecan and for whom bevacizu-
mab plus infusional 5FU/LV and irinotecan allowed a
28.5% response rate with 57% of stabilized patients [34].
Median PFS was 3.9 months and OS was 10.9 months.
In our study, bevacizumab was well tolerated, with only
one interruption due to a reversible posterior leukoen-
cephalopathy syndrome associated with hypertension
[14]. The other adverse events were easily manageable. As
concerns chemotherapy-induced toxicity, it was relatively
low because most of the patients previously received the
same regimen as that associated with bevacizumab. There-
fore required dose modifications were already performed
before starting bevacizumab therapy
Conclusion
Taking together, these results from retrospective data sug-
gest that bevacizumab combined with FOLFOX or FOLF-
IRI may have the possibility to be active in
chemorefractory and selected mCRC patients who did not
receive it previously.
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